MedPath

Expressive Writing in GVHD

Early Phase 1
Terminated
Conditions
Graft Versus Host Disease
Interventions
Behavioral: Expressive Writing
Registration Number
NCT05694832
Lead Sponsor
Northwestern University
Brief Summary

Graft-versus-host-disease (GVHD) is a disease phenomenon that occurs when immune cells of the donor recognize and attack healthy tissue within the transplant recipient, or host. It is ultimately the result of the same immunological mechanisms that provide benefit to patients receiving hematopoietic stem cell transplantation (HSCT). In patients with hematologic malignancies, HSCT can be therapeutic, as donor T cells recognize and mount a response against cancerous cells. HSCT is also used in the setting of certain immunodeficiencies and inborn errors of metabolism for which therapeutic benefit is found in immunologic repletion.

To our knowledge, support groups have yet to be investigated in academic literature as a nonpharmacologic, therapeutic intervention for cutaneous GVHD patients to improve their distress, systemic disease, and quality of life. Given the dearth of research on nonpharmacologic therapies for cutaneous GVHD that address quality of life impairments, we seek to characterize the effect of an expressive writing and peer helping intervention contextualized within the framework of a support group. The primary goal of this study is to provide preliminary efficacy data of expressive writing as an intervention in patients with cutaneous GVHD to trial.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
3
Inclusion Criteria
  • Patients must have an active or previously diagnosed chronic cutaneous graft-versus-host disease (cGVHD).
  • Patients must be age ≥18 years.
  • Patients must be able to write using a utensil and paper or be able to type.
  • Patients must have access to internet or cellular connectivity with sufficient bandwidth to participate in videoconferences (Zoom).
  • Patients should be able to and planning to attend all four live videoconferencing sessions for the support group via Zoom.
  • Patients must have the ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria
  • Patients with limited level of oral and written English.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Expressive writing weekly sessionExpressive WritingWeekly, 1-hour sessions of creative writing, discussion and social support, in a group setting via videoconference for a total of 4 sessions.
Primary Outcome Measures
NameTimeMethod
Change in Dermatology Life Quality Index scores4 weeks

Measured at baseline and post completion of the 4 week expressive writing sessions

Secondary Outcome Measures
NameTimeMethod
Change in Short Form-36 scores4 weeks

Measured at baseline and post completion of the 4 week expressive writing sessions

Trial Locations

Locations (1)

Department of Dermatology, Northwestern University Feinberg School of Medicine

🇺🇸

Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath